Bellevue Life Sciences Acquisition Corp. is a blank check company. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Bellevue Life Sciences Acquisition Corp. is based in Bellevue, Washington.
| Revenue (Most Recent Fiscal Year) | $2.91M |
| Net Income (Most Recent Fiscal Year) | $-27.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.55 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -814.53% |
| Net Margin (Trailing 12 Months) | -363.26% |
| Return on Equity (Trailing 12 Months) | -7.24% |
| Return on Assets (Trailing 12 Months) | -5.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.16 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.14 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 7.84 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.95 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.33 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 35.10M |
| Free Float | 22.19M |
| Market Capitalization | $14.60M |
| Average Volume (Last 20 Days) | 1.40M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 36.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |